Amgen Stock Soars as Biotech Giant Continues to Outperform
Amgen Inc., headquartered in Thousand Oaks, California, is a leading biotechnology company that discovers and develops innovative medicines for serious diseases. The company's market capitalization is approximately $233.8 billion, making it a 'mega-cap stock' with significant influence within the general drug manufacturers industry.
Amgen's strong portfolio of therapies includes Repatha, Prolia, and Enbrel, alongside a growing oncology pipeline. Its exceptional profitability, product-sales growth, and international expansion demonstrate strong demand, operational efficiency, and potential for continued growth.
In recent months, Amgen's stock has performed well, gaining 32.1% year-to-date and 51.4% over the past 52 weeks. This outperforms the Invesco Pharmaceuticals ETF (PJP), which has gained 21.7% year-to-date and 40.2% over the same period.
On August 4, Amgen's shares rose about 2.9% after reporting its Q2 results, exceeding Wall Street expectations with adjusted EPS of $6.29 and revenue of $10.05 billion.